ÂÜÀòÂÒÂ×

Ruth Tal-Singer, PhD, President & Chief Scientific Officer at the COPD Foundation is internationally recognized as an innovative, patient-focused and highly analytical health care leader and clinical scientist with extensive Research and Development experience. She has a proven history of successfully leading international public and private partnerships and non-profit organizations through critical advancements and progress of clinical trials and large observational cohorts. She is adept at building and maintaining partnerships between Pharma, patients, academia and governments. Her wide-ranging technical and scientific knowledge comprises molecular biology, immunology, application of digital technology and in vivo disease models (pre-clinical and clinical). Ruth led the initial clinical development of GSK’s inhaled anti-muscarinic portfolio, currently available to patients as umeclidinium bromide. She has authored 160+ peer-reviewed articles including highly-cited scientific publications (h-index 66). Ruth was the Industry Co-Chair of the COPD Biomarker Qualification Consortium (CBQC) from its inception in 2010 and up to her retirement from GSK in October 2019.